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Abstract
The exchange proteins activated by cAMP (EPAC) are implicated in a large variety of physiological processes and they are 
considered as promising targets for a wide range of therapeutic applications. Several recent reports provided evidence for 
the therapeutic effectiveness of the inhibiting EPAC1 activity cardiac diseases. In that context, we recently characterized a 
selective EPAC1 antagonist named AM-001. This compound was featured by a non-competitive mechanism of action but the 
localization of its allosteric site to EPAC1 structure has yet to be investigated. Therefore, we performed cosolvent molecular 
dynamics with the aim to identify a suitable allosteric binding site. Then, the docking and molecular dynamics were used to 
determine the binding of the AM-001 to the regions highlighted by cosolvent molecular dynamics for EPAC1. These analyses 
led us to the identification of a suitable allosteric AM-001 binding pocket at EPAC1. As a model validation, we also evaluated 
the binding poses of the available AM-001 analogues, with a different biological potency. Finally, the complex EPAC1 with 
AM-001 bound at the putative allosteric site was further refined by molecular dynamics. The principal component analysis 
led us to identify the protein motion that resulted in an inactive like conformation upon the allosteric inhibitor binding.
Keywords EPAC · Molecular Dynamics · Cosolvent Molecular Dynamics · Docking · PCA
Introduction
The cyclic adenosine monophosphate (cAMP) is a universal 
second messenger that regulates many biological processes, 
including cell proliferation, differentiation, and apoptosis 
[1]. The effects of cAMP in mammalian cells are mediated 
by at least three effector families: protein kinase A (PKA), 
exchange proteins activated by cAMP (EPAC) and ion chan-
nels bearing a cyclic nucleotide binding domains (CNBD). 
The EPAC proteins regulate a variety of physiological pro-
cesses, such as calcium homeostasis in cardiomyocytes, 
insulin secretion from pancreatic β cells, integrin-mediated 
cell adhesion, and cell death [2]. Therefore, EPAC proteins 
are considered as targets for a wide range of therapeutic 
applications [3]. To date, two EPAC isoforms have been 
identified, EPAC1 and EPAC2 which display distinct pat-
tern of tissue expression. Indeed, EPAC1 is ubiquitously 
expressed whereas EPAC2 and its slice variants are localized 
in the brain (EPAC2A), pancreatic cells (EPAC2B) testis and 
liver (EPAC2C) [4].
EPAC1 and EPAC2 are multidomain proteins featured 
by an N-terminal regulatory region (RR) and a C-terminal 
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catalytic region (CR). The amino-terminal regulation region 
contains a Disheveled/Egl-10/pleckstrin (DEP) domain fol-
lowed by a cyclic nucleotide-binding domain (CNBD). 
EPAC2A has an additional low-affinity CNBD, which is 
unable to induce guanine nucleotide exchange factor (GEF) 
activity after cAMP binding [5]. The catalytic region con-
sists of a Ras exchange motif (REM), a Ras association 
domain (RA) and a CDC25 homology domain (CDC25HD). 
The CDC25HD catalyses GDP-GTP exchange for Rap, while 
the REM domain contributes to stabilize a catalytic helix, 
and the RA domain influences EPAC subcellular localization 
[6]. The regulatory CNBD at the RR C-terminus [7, 8] con-
trols the relative orientations of the RR and CR with respect 
to each other. In the absence of cAMP, the two regions adopt 
a closed conformation, in which the RR restricts access of 
the Rap GTPases to the CR, resulting in constitutive inhibi-
tion. Upon binding of cAMP to the conserved CNBD, the 
two regions adopt an open (active) topology, where the Rap 
substrate can interact with the CR to promote GDP-GTP 
exchange [7–10] (Fig. 1).
In the heart, cAMP represents one of the most important 
mechanism for increasing cardiac function in response to 
acute sympathetic stimulation of β-adrenergic receptor (β 
-AR) [11]. Although acute activation of b-AR has beneficial 
effect on cardiac function, chronic b-AR stimulation of this 
pathway promotes pathological cardiac remodelling, which 
may ultimately lead to heart failure (HF) [12]. Importantly, 
recent data show pharmacological or genetic inhibition of 
EPAC1 prevents cardiac hypertrophy and fibrosis induced 
by sustained β-AR activation and improves cardiac function 
[13].
Therefore, targeting EPAC1 may have potential therapeu-
tic benefits in cardiac diseases [13, 14] (Fig. 1).
Currently, there are only few EPAC1 modulators [14]. 
Based on their chemical structure these compounds may 
be divided in cAMP analogue and non-nucleotidic small 
molecules. The major drawbacks about the reported 
modulators were the lack of selectivity between the EPAC 
isoforms or PKA, and the unsuitable drug-like properties. 
Another concern about modulator of cAMP-regulated pro-
tein is that the orthosteric cAMP site is amply conserved 
making selectivity a crucial issue [15]. This task may be 
solved looking for non-competitive allosteric modulator 
that is expected to have reduced risks of cross-reactivity 
with other receptors that signal via cAMP such as PKA or 
CNG ion channels [16]. To our knowledge there are just 
two compounds, CE3F4 [17, 18] and AM-001 [13], that 
are able to selectively inhibit EPAC1. The small molecule 
AM-001 is a thieno[2,3-b]pyridine derivative (Table S1) 
acting as a selective non-competitive antagonist of EPAC1 
[13]. AM-001 mitigates cardiac hypertrophy, inflammation 
and fibrosis, and improves cardiac function during chronic 
β-adrenergic receptor activation. In in-vivo experiments, 
AM-001 reduces the infarct size after mouse myocardial 
ischaemia/reperfusion injury [13].
Since the biological evaluation suggested a non-com-
petitive mechanism of action for the AM-001 derivative 
[13] we sought to identify its putative allosteric bind-
ing site. To date, there are not experimental data about 
the allosteric site localization. It was just reported that 
the hinge region of EPAC might be a druggable region 
because of its crucial role in the close to open conforma-
tion transition [19, 20].
The cosolvent molecular dynamics (CMD) method is 
very useful to highlight both catalytic and allosteric sites 
[21]. This method was inspired by the multiple solvent crys-
tal structures (MSCS) technique [22]. The MSCS is based on 
solving crystal structures of proteins in the presence of vari-
ous organics cosolvents. Overlapping locations of different 
cosolvents were found to be highly correlated with regions 
of biological significance [21]. The CMD could be consid-
ered the in-silico counterpart of the MSCS experiments. The 
CMD method uses the molecular dynamics simulation of a 
protein solvated by an organic solvents/water mixtures to 
Fig. 1  Graphical representation of EPAC activation upon cAMP 
binding. CNBD, DEP, REM, RA, and CDC25-HD domains are col-
oured in yellow, blue, cyan, orange and red respectively. cAMP is 
reported as white stick, RAP is reported as green cartoon. The cyclic 
nucleotide binding allows the regulatory domain to open leading the 
catalytic region exposed for binding of Rap
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determine the sites where the organics solvents preferen-
tially bind.
In our work, we attempted to identify the EPAC1 allos-
teric binding site by using CMD. Thus, the EPAC1 active 
and inactive conformations were solvated with a solution 
of 20% (w/w) of isopropanol (ISO), ethanol (ETOH), and 
dimethylsulfoxide (DMSO), in water, then the cosolvent 
occupancy maps were generated and investigated.
ISO is the most used solvent for CMD as it is able to 
interact with hydrophobic protein sites [23]. DMSO and 
ETOH are chosen for their hydrogen-bond acceptor and 
donor capabilities respectively [24, 25]. The cosolvents were 
also chosen to be fully water miscible to avoid molecules 
aggregations phenomena and the concentration was fixed to 
avoid protein denaturation [26].
The models of the inactive and active EPAC1 conforma-
tions were generated by homology from the EPAC2 crystal 
structure (inactive state: PDB code 2BYV [27]; active state 
PDB code 3CF6 [6]).
To evaluate that the unfolding phenomena did not affect 
the protein during the simulations the RMSD of the back-
bone Cα was computed [28]. The RMSD values showed 
that cosolvents molecules did not disturb the protein folding 
(Figs. S1, S2).
The trajectory of each simulation was analysed to deter-
mine the cosolvent occupancy maps. Each map indicates 
the pockets where the cosolvent molecules were most fre-
quently located. The interaction energy among protein and 
cosolvent molecules was not taken into account. A size cut-
off was applied to remove the smaller disconnected part of 
the maps doing interpretation easier. Thus, the protein areas 
where the cosolvent occupancy maps were superimposable, 
represented the suitable sites for a partner binding (Figs. 2 
and 3 and S3, S4).
Materials and methods
EPAC structures
The EPAC structure was downloaded from the PDB data 
bank (http://www.rcsb.org/), inactive state: PDB code 
2BYV; [27] active state PDB code 3CF6 [6].
Homology model were carried out by homology model 
PRIME [29] of MAESTRO [30]. The obtained models were 
examined to avoid steric clashes, bond length deviations and 
angles, etc., by using the Ramachandran plot and the Protein 
Preparation Wizard. [31] The missing loops were obtained 
by Raptor X [32, 33]. The primary sequence of EPAC1 and 
EPAC2 was downloaded by UniProtKB (https ://www.unipr 
ot.org) code: O95398NCBI and UniProtKB code: Q8WZA2 
respectively.
Molecular dynamics
Molecular dynamics was performed with the AMBER 12 
suite [34]. For simulation in water the protein was solvated 
in a periodic octahedron simulation box using TIP3P water 
molecules, providing a minimum of 10 Å of water between 
the protein surface and any periodic box edge. The organic 
cosolvent/water box were prepared by packmol by fixing a 
20% w/w ratio [35]. Parameters for cosolvents were obtained 
by pyMDMix. (http://mdmix .sourc eforg e.net) Then, ions 
Fig. 2  Epac1 active confor-
mation cosolvent occupancy 
maps selected areas. Epac1 is 
reported as cartoon: CNBD 
and DEP green; REM orange; 
CDC25-HD blue and RA red. 
Yellow maps are for ETA; cyan 
for ISO and pink for DMSO
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were added to neutralize the charge of the total system. The 
solvents molecules and the ions were energy-minimized 
keeping the coordinates of the protein-ligand complex fixed 
(1000 cycle), and then the whole system was minimized 
(5000 cycle). Following minimization, the entire system 
was heated to 298 K (20 ps). The production simulation 
was conducted at 298 K with constant pressure and periodic 
boundary condition. Shake bond length condition was used 
(ntc = 2). Production was carried out on GeForce gtx780 
gpu. The cosolvent occupancy maps were computed with 
trajectories length of 100 ns and 250 ns. The obtained maps 
were similar regardless the length of the trajectories.
The production length of the simulations to evaluate the 
AM-001 stability at the studied sites was 10 ns. The pro-
duction time to run PCA was 200 ns. All simulations were 
repeated five times. The occupancy maps were calculated 
by Chimera Volume viewer [36]. Chimera we also used for 
the representation of the maps by volume viewer range 50%, 
and for the size filtering by the Hide Dust tool size 5.0 [37]. 
Compounds were parametrized by Antechamber [38, 39] 
using BCC charges. Trajectories analysis were carried out 
by cpptraj program [40].
PCA
The PCA analyses were carried out by cpptraj program 
[40]. The trajectory was firstly superimposed to an average 
structure obtained by cpptraj. Then, the trajectory of the 
a-carbon was extracted and the covariance matrix calculated. 
The diagonalization of the covariance matrix generated a 
set of eigenvectors that gave a vectorial description of the 
motion. The computed eigenvectors and eigenvalues were 
used to draw the porcupine plot by means of the Normal 
Mode Wizard module (NMWiz) [41, 42] of the VMD gui 
[43].
Molecular docking
Ligand structures were built with MAESTRO [30] and mini-
mized using the OPLS3 force field until a rmsd gradient of 
0.05 kcal/(mol Å) was reached. The docking simulations 
were performed using Gold, [44] Plants [45] and Autodock 
[46]. We set a binding lattice of radius or side large enough 
to cover the whole studied maps, then all default settings 
were used. The Docking of the AM-001 analogues were car-
ried out by Plants [45], using as receptor a representative 
structure obtained by the trajectory of the EPAC1/posa3_6. 
The representative structure was the average structure 
extracted by cpptraj [40] after a stable rmsd was reached. 
The poses binding free energy was calculated by MAESTRO 
prime MMGB-SA module [47]. The pictures reported in the 
manuscript were done with Pymol [48].
Results and discussion
Analyses of active conformation occupancy maps
The active conformation of the enzyme was mainly stud-
ied to access the quality of the method. The inhibition of 
EPAC1 by AM-001 was previously determined by BRET 
assays [17]. Indeed, the experiment measured the level of 
activation of the EPAC1, namely the shift from inactive to 
active form of the enzyme after the antagonist binding. The 
cosolvent occupancy maps were computed with trajectories 
Fig. 3  Epac1 inactive conformation cosolvent occupancy maps selected zones. Epac1 inactive conformation isreported as cartoon: CNBD and 
DEP green; REM orange; CDC25-HD blue and RA red. Yellow maps are forETA; cyan for ISO and pink for DMSO
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of 100 ns (Fig. S3) and 250 ns (data not shown). The occu-
pancy maps analyses for the EPAC1 active conformation led 
to the identification of four interesting zones signed as areas 
from 1 to 4 (Fig. 2) regardless of the trajectories length.
The areas 1 and 2 were located at the CDC25-HD domain 
and corresponded to the Rap binding site [6]. Indeed, the 
superimposition of the EPAC2 crystal structure (PDB 
code: 4MGI) [49], bearing Rap interacting domain, with 
the EPAC1 model clearly showed that the areas 1 and 2 
were filled by this domain. Specifically, we observed that 
the area 1 involved 4 α helices of the CDC25-HD namely α1 
(671–680), α3 (708–713), α5 (750–756) and α9 (839–844). 
This area bound the β4 and the loop linking β4 to α3 of 
the Rap domain. (Fig. S5) The area 2 involved the CDC25 
Helical Hairpin (α9 and α10 from 823 to 854) that accom-
modated the loop between α1 and β2 of Rap [50]. (Fig. S5) 
The area 2 was also reported to be potentially involved in an 
interaction between EPAC1 and RanPB2 [51].
The site 3 was located at the interface between the 
CDC25-HD and RA domains, and comprised a loop absent 
in EPAC2. This broad surface encompassed part of the 
loop (550–557), the CDC25-HD α1 (678–682) and the β1 
(558–562) of RA domain. This area was reported to be suit-
able for a protein-protein interaction [52].
The area 4 was located at the REM domain. It comprised 
the α1 (394–398) and α3 (434–440) helices of REM and a 
small loop of CNBD (294–299). This zone was identified 
to be suitable for partners binding by FTPmap experiments 
[20].
Various proteins with undefined binding pockets, con-
tributed to the regulation and/or the subcellular localization 
of EPAC1 [51]. Indeed, it was reported that the residues 
838–881 were involved in the compartmentalization of 
EPAC1, but it was not clarified how these residues drove 
this activity [52]. Furthermore, tubulin was also reported as 
a direct partner of EPAC1, but its binding site was not yet 
identified [53]. Our analyses of the occupancy maps sug-
gested that some areas were suitable for binding of partner 
proteins are consistent with the available structural data, 
validating the appropriateness of the method used.
Occupancy maps analyses of inactive conformation
The CMD procedure was then applied to the EPAC1 auto-
inhibited form (inactive conformation) with the aim to 
identify a putative binding site for AM-001. The cosolvent 
occupancy maps were computed by trajectories of 100 ns 
(Fig. 3) and 250 ns (Fig. S6). The analyses of the cosolvent 
occupancy maps did not show any significant differences 
depending on the trajectories length and led to the identifica-
tion of some attractive areas. The proposed mechanism of 
cAMP-induced EPAC1 activation involves EPAC1 regula-
tory domain that moves away from the catalytic domain. In 
this transition a crucial role is played by the lid (first β-strand 
of REM 384–391 and the tip of CDC25-HD HP 832–837) 
and the hinge helix (CNBD 299–308). Accordingly, AM-001 
binding to its allosteric pocket should have to impair this 
cAMP-dependent conformational change [20]. These data 
were used to reject the area located at the CDC25-HD and 
the RA domains. Indeed, the areas appear to be too far from 
both the lid and hinge helix to influence the inactive to active 
conformation state. This observation led us to managed 7 
areas (Fig. 3).
Area 1 was the cAMP binding pocket [6]. The identifica-
tion of the cAMP site further validated the reliability of the 
method.
The remaining areas were inspected by docking and 
molecular dynamics. Area 2 was located at the CNBD close 
to the catalytic site and it encompassed CNDB α3 and the 
following loop (245−250), α4 (251–260) and α6 (344–350). 
Area 3 was at the interface between CNBD and REM 
domains. This site is delimited by REM β1 (387–392) and α1 
(398−402) together with the CNBD β9 (353–359) and β10 
(363−368). Area 4 involved the HP loop of CDC25-HD and 
the REM α2 (423−430). Area 5, was the only one entirely 
located at the CDC25-HD comprising the α2 (689−692), 
α3 (704−708), α5 (761−765) and α9 (815−827). The area 
6 was at the interface of CDCD25-HD and REM. The area 
was defined by the α8 (800–805), α9 (817–822) and α10 
(844–851) of CDC25-HD and the loop between α2 and α3 
(247–251) of the CNDB. Lastly, area 7 was located between 
the CDC25-HD and the CNDB domains involving the α8 
(793–801) of the CDC25-HD and the long helix (206–216) 
linking CNDB to the Dep domain. (Fig. S7)
Thus, AM-001 was docked to each of the listed areas. The 
docking studies were carried out with Gold, [44] Plants [45] 
and Autodock [46].
For each area, at least one consistent AM-001 binding 
pose (RMSD < 1.5 Å) among the docking software was 
selected and submitted to molecular dynamic simulations 
(10 ns).
For the areas 2, 3, 4 and 7 the analyses of the molecular 
dynamic trajectories showed that the ligand moved out of 
the pocket at the early stage of the simulation. In fact, these 
sites were markedly solvent exposed. This feature was not 
common for small molecules binding site [54, 55], and it was 
therefore hypothesized that these sites were more appropri-
ate as protein-protein interaction pocket [56, 57].
Then we managed the two remaining areas, namely 5 and 
6. Once again, the selected binding poses were submitted to 
molecular dynamics simulations. The trajectories analysis 
showed two stable (rmsf < 1.0 Å) binding modes for area 5 
(termed as pose4_5 and pose9_5) (Figs. S9, S10) and one 
for area 6 (termed as pose3_6).
Since AM-001 preferentially bound to the EPAC1 
isoforms  (IC50EPAC1 48.5 µM), and it was ineffective in 
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suppressing EPAC2 activity  (IC50EPAC2 > 1000 µM) [13] 
we investigated whether the 3 selected binding mode 
might be suitable for EPAC2. Thus, we carried out a series 
of molecular dynamics simulations of the 3 binding modes 
placed in the corresponding pockets of EPAC2. The tra-
jectories and the binding free energy were calculated [58, 
59] and compared with those resulting from the EPAC1 
simulations.
The trajectories inspection showed that the poses for area 
5 were stable for EPAC2 (pose4_5 rmsf 0.49 Å pose9_5 
rmsf 0.39 Å) as observed for EPAC1 (pose4_5 rmsf 0.41 Å 
pose9_5 rmsf 0.60 Å). The computed binding free ener-
gies for EPAC1 and EPAC2 were very similar (EPAC1 ΔG 
pose4_5 = − 53.9, pose9_5 = − 56.1; EPAC2 ΔG pose4_5 
= − 63.3 pose9_5 = − 53.1). The difference was just 3 
Kcal/mol for pose9_5, and a difference of 10 Kcal/mol for 
pose4_5 with the best ΔG value for EPAC2.
These data could indicate that area 5 is not be suitable 
for binding of AM-001 as a selective allosteric inhibition 
of EPAC1. This site could however correspond to a region 
of biological significance for the enzymatic activity of both 
EPAC isoforms.
The same analysis was repeated also for the area 6 pose 
(pose3_6). The complex EPAC2/pose3_6 was submitted to 
molecular dynamic. The trajectory inspection clearly showed 
a level of instability. The compound moved toward the sol-
vent, showing a rmsd higher than 3 Å and a calculated ΔG 
of -45.9 kcal/mol. The complex EPAC1/pose3_6 trajectory 
was inspected in the same way. The AM-001 pose showed a 
general stability with a rmsd of 1.19 Å and a calculated ΔG 
of -65.1 kcal/mol, thus with about 20 kcal/mol in favour of 
the EPAC1 binding.
These data suggested that area 6 might be the most suita-
ble for the EPAC1 allosteric inhibition. To validate our idea, 
we extended the molecular dynamic simulation to 200 ns 
and we testes the ability of this binding site to match known 
SARs profile of the compound analogues (Table S1).
The analyses of the extended trajectory showed that the 
selected binding mode was stable and led us to identify a 
series of pharmacophoric interactions: the fluorinated phenyl 
group had a pi-cation interaction with R801 side chain and 
hydrophobic contacts with L235 and M; the primary amine 
moiety as well as the amidic nitrogen atom were involved in 
H-bond with D234 side chain; the pyridine thiophene fused 
ring had hydrophobic contacts with F237, R255, I825 and 
M844 side chains; the unsubstituted phenyl ring was trapped 
by pi-cation contacts with R847 and R850; the thiophene 
ring lay in a hydrophobic pocket mainly formed by R377, 
P378, N260 and N838 side chains; Furthermore, the thio-
phen aromatic ring behaved as weak H-bond acceptor [60] 
for the asparagine side chain amide moieties (Fig. 4). These 
interactions were stable through the simulation time con-
firming the stability of the proposed binding site.
With the aim to clarify the reason that were responsi-
ble for the selectivity of AM-001 between the two studied 
EPAC isoforms, we compared the two binding sites. The 
main difference deals with the residues of the loop between 
the CNBD b10 and REM b1. The loop was 19 residues long 
for EPAC1 and 18 residues long for EPAC2. Despite the 
similar length, just two residues were conserved between 
the two isoforms. Furthermore, the four residues facing the 
binding pocket for EPAC1(RPPT) were very different from 
the residues in the same positions of EPAC2 (NQGN). Thus, 
it may be argued that the behaviour of this loop in terms of 
conformation and interactions with AM-001 is responsible 
for the selectivity. Furthermore, R847 and I825, involved 
in contacts with AM-001 change to N (956) and T (934) 
respectively in EPAC2, weakening the binding stability. 
Also, D239 in EPAC1 correspond to E (345) in EPAC2. 
Taken together these data provide a possible explanation of 
the AM-001 selectivity toward EPAC1.
Then we docked the nine AM-001 analogues (Table S1) 
into this binding site, to evaluate the ability of the site to fit 
the experimental data [13]. The compounds AM-004 and 
AM-005 which differs just for the fluorine atom position 
had a very similar binding mode to AM-001, sharing the 
same interactions. For the compounds AM-003, AM-006, 
AM-007, AM-008 and AM-009 the binding mode was also 
comparable to AM-001, albeit with some evident differ-
ences: we did not observe the contacts of the fluorinated 
phenyl ring (AM-003 and AM-006), the thiophene (AM-007 
and AM-008), and the unsubstituted phenyl ring (AM-009) 
of AM-001. For compound AM-002 we obtained a bind-
ing mode similar to AM-001, but we did not observe any 
H-bonds, and the pyrimidone linked phenyl ring was place 
Fig. 4  Proposed binding mode for AM-001 (cyan). Epac1 is reported 
as cartoon: CNBD and DEP green; REMorange; CDC25-HD blue 
and RA red. Surface is reported in grey. Residues involved in interac-
tions were depictedas grey stick. H-bond was reported as yellow dot-
ted lines
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father from the R801 (Fig. S10). Furthermore, we obtained 
a good correlation between the computed binding energy 
for the docking poses [30, 47] and the experimental bio-
logical activity with a significant correlation coefficient, R, 
of 0.74 and Rs of 0.83 p (2-tailed) 0.53% (Table S2). The 
selected binding mode reasonably fits the SAR for AM-001 
analogues. In conclusion, the selected binding mode rea-
sonably fits the published structure-activity relationship for 
the AM-001 analogues, and seems suitable as a selective 
allosteric binding site for the inhibitor AM-001.
Lastly, we analysed the EPAC1/AM-001 complex trajec-
tory with the aim of understanding how the AM-001 bind-
ing impaired the activating transition of the enzyme. PCA 
analysis was carried out to highlight the dominants mode of 
motion of the protein during the simulation time [61–63]. 
These protein motions were visualized by porcupine plots 
[64, 65] (Fig. 5) that show the direction and magnitude of 
the top two eigenvectors (Fig. S12) for each of the back-
bone Ca atoms. The most prominent observed motion was 
related to the loops at the CDC25-HD. Focusing on the 
helices that shaped the binding site we observed that a7 
(794–805), a8 (821–830) and a9 (840–850) helices of the 
CDC25-HD moved toward the CNBD, as well as the CNBD 
a2 (230–242) moved toward the CDC25-HD.
The observed movements involved the enzyme loop 
and helices that are crucial in the open -to-close confor-
mational transition. Thus, AM-001 binding to area 6 in the 
closed conformation of EPAC1 might strengthen the contact 
between the CDC25-HD and the CNBD domains, stabilizing 
an inactive-like conformation and preventing the activation 
transition otherwise induced by cAMP binding to the CNBD 
domain.
Conclusions
Cosolvent molecular dynamics were performed with the 
aim to characterize a putative binding site for the EPAC1 
allosteric inhibitor AM-001. By the cosolvent occupancy 
maps analyses we identified the EPAC1 most suitable 
sites for a partner binding. Each site was evaluated by the 
docking and molecular dynamics of AM-001. The pocket 
located at the interface between a8, a9 and a10 of CDC25-
HD and a2 and a3 of CNBD seems suitable as a selec-
tive allosteric binding site for the AM-001. The available 
AM-001 analogues were docked to this site showing a 
good match with the already reported SAR [13]. The PCA 
analyses of the EPAC1/AM-001 trajectory highlighted that 
the AM-001 binding might strengthen the contact between 
CDC25-HD of the catalytic region and CNBD of the regu-
latory region stabilizing an inactive “like” conformation. 
Thus, AM-001 binding to the predicted binding pocket 
may constrain the highly dynamic EPAC1 in an inhibited 
conformation, despite the binding of cAMP.
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